Medical topics worthy of writing about transcend the details of the drug or device and implicate a broader lesson. The medical establishment's turn against digoxin perfectly illustrates this duality.

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...

At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...

Most of the estimated 400 000 Canadians who experience heart failure are 65 years of age or older. Heart failure is the most frequent reason for hospital admission for older adults. Admission for ...

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20 percent, according to recent results. The findings suggest that caution may be needed when using ...

This page lists all known medications that could potentially lead to 'Digoxin effect' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Protective effects have been suggested for digoxin against prostate cancer risk. However, few studies have evaluated the possible effects on prostate cancer-specific survival. We studied the ...

Patients with atrial fibrillation (AFib) who are given digoxin to control their symptoms have an increased risk of death, whether or not they have a diagnosis of heart failure, compared with patients ...

A drug commonly used to treat heart conditions, Digoxin, was associated with a 72 percent higher rate of death among adults with newly diagnosed systolic heart failure. This is according to a Kaiser ...

In patients with heart failure with reduced ejection fraction (HFrEF) who have an implantable cardioverter-defibrillator (ICD), the use of digoxin may increase the risk of ventricular tachyarrhythmia ...

C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes-difficult-to-get drug. The ...